Herpes News and Research

RSS

Herpes is an infection caused by two different but closely related viruses — herpes simplex virus type 1 (HSV-1) or cold sores and herpes simplex virus type 2 (HSV-2) or genital herpes. Both are easy to catch. They have similar symptoms (blisters or sores) and both can occur on different parts of the body. When the infection is on the mouth, it is called oral herpes. When it is on or near the sex organs, it is called genital herpes. There is no cure for herpes. Treatments are available to speed up the healing of the genital sores.

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate.

21 Apr 2014

Scientists develop microbicide gel that prevents transmission of multiple STIs in vagina/rectum in animals

Population Council scientists and their partners have found that their proprietary microbicide gel is safe, stable, and can prevent the transmission of multiple sexually transmitted infections (STIs) in both the vagina and rectum in animals: HIV, herpes simplex virus 2 (HSV-2), and human papillomavirus (HPV).

18 Apr 2014

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%.

15 Apr 2014

Herpes simplex viral therapy in conjunction with radiation proves effective in treating malignant gliomas

Researchers at the University of Alabama at Birmingham report a genetically engineered herpes simplex viral therapy is safe when used in conjunction with radiation in the treatment of malignant gliomas, one of the most deadly forms of brain cancer.

9 Apr 2014

Patients' risk of stroke increases following shingles, but antiviral drugs appear to offer protection

Patients' risk of stroke significantly increased following the first signs of shingles, but antiviral drugs appeared to offer some protection, according to a new study in Clinical Infectious Diseases, now available online.

3 Apr 2014

BioAlliance Pharma, Daewoong sign new licensing agreement for commercialization of Sitavig in South Korea

BioAlliance Pharma SA, an innovative Company specialized in the development of drugs in orphan oncology diseases, today announces an exclusive supply and license agreement for Sitavig® (Acyclovir Lauriad®) with Daewoong Pharmaceutical Co., Ltd. for commercialization rights in South Korea.

2 Apr 2014

Experimental vaccine for HSV-2 infection reduces rate of viral shedding at 6 months

Updated Phase 1/2a results with GEN-003, a vaccine candidate under development by Genocea Biosciences, Inc. (Nasdaq: GNCA) for the treatment of herpes simplex virus type 2 (HSV-2) infection, showed the experimental vaccine to generate highly significant reductions in both the number of clinical lesion days and rate of viral shedding at six months after the final vaccine dose.

27 Mar 2014

Johns Hopkins researchers identify protein that regulates the body's immune response to CMV

Infectious disease specialists at the Johns Hopkins Children's Center have identified a protein that regulates the body's immune response to cytomegalovirus (CMV), a common pathogen that causes lifelong infections and can lead to devastating illness in newborns and those with weakened immune systems.

27 Mar 2014

CLL patients more prone to infections due to reduced number of antibodies

People with chronic lymphocytic leukaemia (CLL) are essentially more prone to infections such as varicella, influenza or pneumococci due to the reduction in the number of antibodies that their condition causes.

19 Mar 2014

Researchers suggest potential treatment target for HCMV infection

Discovering where a common virus hides in the body has been a long-term quest for scientists. Up to 80 percent of adults harbor the human cytomegalovirus (HCMV), which can cause severe illness and death in people with weakened immune systems.

11 Mar 2014

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Agenus Inc., a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced its financial results and business highlights for the fourth quarter and year ended December 31, 2013.

5 Mar 2014

Women using DMPA injection more likely to acquire HIV than women using NET-EN

Women who used an injectable contraceptive called DMPA were more likely to acquire HIV than women using a similar product called NET-EN, according to a secondary analysis of data from a large HIV prevention trial called VOICE, researchers from the National Institutes of Health-funded Microbicide Trials Network reported today at the 21st Conference on Retroviruses and Opportunistic Infections in Boston.

5 Mar 2014

Loyola physician sheds light on common and painful viral infection, shingles

Shingles is a painful viral infection that affects almost one million people worldwide and 30 percent of Americans every year.

4 Mar 2014

FDA approves sNDA to include radiographic data updating label of Pfizer XELJANZ for treatment of RA

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to update the current label of XELJANZ® (tofacitinib citrate) 5 mg tablets to include radiographic data from two Phase 3 studies, ORAL Scan (A3921044) and ORAL Start.

25 Feb 2014

Researcher receives Pioneer Award for engineering herpes simplex virus gene delivery systems

Joseph C. Glorioso, III, PhD (University of Pittsburgh School of Medicine, PA) devoted much of his research career to developing herpes viruses as efficient vectors for delivering therapeutic genes into cells.

20 Feb 2014

Exposure to common infections linked to memory and brain function

Exposure to common infections is linked to memory and brain function - even if the infections never made you ill, according to research presented at the American Stroke Association's International Stroke Conference 2014.

13 Feb 2014

International study examines link between infections and ischemic stroke in children

Common infections are associated with a significantly higher chance of stroke in children, but routine vaccinations may help decrease risk, according to preliminary research (abstract 39) presented at the American Stroke Association's International Stroke Conference 2014.

12 Feb 2014

Spinifex announces results of Phase 2 clinical trial of EMA401 in postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces that The Lancet has published the results of its Phase 2 clinical trial of its lead candidate, EMA401, in postherpetic neuralgia (PHN).

5 Feb 2014

95% of adults die annually from vaccine preventable diseases

While adults make up 95 percent of those who die annually from vaccine preventable diseases, a new study from the University of Colorado School of Medicine shows their vaccination rates remain stubbornly low, representing a growing public health concern.